CCL24   Click here for help

GtoPdb Ligand ID: 775

Synonyms: eotaxin-2
Immunopharmacology Ligand
Compound class: Endogenous peptide in human, mouse or rat
Comment: CCL24 is a CC family chemokine. It can promote recruitment and activation of both immune cells and fibroblasts and this combined action induces over-production of extracellular matrix components that underlie uncontrolled inflammation and fibrotic changes. Based on evidence that CCL24 is a driver of inflammation and fibrosis in human diseases such as primary sclerosing cholangitis (PSC) [2], systemic sclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) it is being investigated as a therapeutic target for these types of disease.
Species: Human
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. FDA. 
Monoclonal antibody targeting CCL24.
Accessed on 13/11/2018. Modified on 13/11/2018. www.accessdata.fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=618317
2. Greenman R, Segal-Salto M, Barashi N, Hay O, Katav A, Levi O, Vaknin I, Aricha R, Aharoni S, Snir T et al.. (2023)
CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis.
JCI Insight, 8 (12). [PMID:37345655]
3. Mor A. (2015)
Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines.
Patent number: WO2015132790A2. Assignee: Chemomab Ltd.. Priority date: 04/03/2014. Publication date: 11/09/2015.
4. Mor A, Friedman S, Hashmueli S, Peled A, Pinzani M, Frankel M, Safadi R. (2024)
Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies.
Drug Saf, 47 (9): 869-881. [PMID:38822943]
5. Morokata T, Suzuki K, Masunaga Y, Taguchi K, Morihira K, Sato I, Fujii M, Takizawa S, Torii Y, Yamamoto N et al.. (2006)
A novel, selective, and orally available antagonist for CC chemokine receptor 3.
J Pharmacol Exp Ther, 317 (1): 244-50. [PMID:16339911]
6. Palikhe NS, Kim SH, Cho BY, Ye YM, Choi GS, Park HS. (2010)
Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease.
Allergy, 65 (3): 338-46. [PMID:19796209]
7. Parody TR, Stone MJ. (2004)
High level expression, activation, and antagonism of CC chemokine receptors CCR2 and CCR3 in Chinese hamster ovary cells.
Cytokine, 27 (1): 38-46. [PMID:15207250]
8. White JR, Imburgia C, Dul E, Appelbaum E, O'Donnell K, O'Shannessy DJ, Brawner M, Fornwald J, Adamou J, Elshourbagy NA et al.. (1997)
Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils.
J Leukoc Biol, 62 (5): 667-75. [PMID:9365122]